Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab

Objective: To assess onset of effect in three placebo- or nonsteroidal anti-inflammatory drug (NSAID)-controlled trials of tanezumab in patients with moderate-to-severe osteoarthritis. Methods: Post-hoc nonparametric Kaplan–Meier analyses were used to estimate median time to first improvement and to...

ver descrição completa

Detalhes bibliográficos
Main Authors: D.J. Hunter, T.J. Schnitzer, J. Hall, D. Semel, I. Davignon, J.C. Cappelleri, A.G. Bushmakin, L. Abraham
Formato: Artigo
Idioma:English
Publicado em: Elsevier 2022-09-01
Colecção:Osteoarthritis and Cartilage Open
Assuntos:
Tanezumab
WOMAC
Osteoarthritis
Time to improvement
Kaplan–Meier
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2665913122000620

Internet

http://www.sciencedirect.com/science/article/pii/S2665913122000620

Registos relacionados